Short answer
Healthpeak Properties (DOC) filed its fiscal 2025 10-K annual report with the SEC on Feb 3, 2026. It reported revenue of $604M (+6.2% year over year) and net income of $71M.
- Top risk flagged: U.S. federal policy shifts (NIH funding cuts, drug pricing, tariffs) creating life science tenant funding uncertainty, risking rent payment and expansion
FY2025 key financial metrics · XBRL
- Revenue
- $604M
- +6.2% YoY
- Net income
- $71M
- −70.7% YoY
- EPS (diluted)
- $0.10
- −72.2% YoY
- ROE
- 1.0%
- −1.9 pp YoY
- Operating cash flow
- $1.3B
- +17.0% YoY
Source: XBRL data from the Healthpeak Properties (DOC) FY2025 10-K on SEC EDGAR. USD.
Healthpeak Properties FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Own, operate, develop high-quality U.S. healthcare real estate focused on outpatient medical, lab, and senior housing properties
- New segment emphasis: Preparation for Janus Living IPO, transferring 34 senior housing communities (10,422 units) into a publicly listed REIT structure under majority ownership
- Strategic shift: Following merger with Physicians Realty Trust, added 299 outpatient medical buildings, expanding scale and tenant base significantly
- Quantitative metric: Portfolio grew to 689 properties at 12/31/2025; senior housing includes 34 properties plus acquiring remaining 46.5% of SWF SH JV in Jan 2026
- Noteworthy fact: Senior housing segment redefined to combine life plan communities with sovereign wealth fund JV, reflecting new reportable segment structure for 2025
Management Discussion & Analysis
- Revenue from resident fees and services $568M in 2024, up $41M YoY from $527M
- Adjusted NOI $159.6M in 2024 vs $135.6M in 2023, +17.7% YoY, driven by higher fees and occupancy despite higher expenses
- Best segment: Merger-Combined Same-Store with 17.7% NOI growth; no explicit worst segment disclosed
- Operating cash flow $1.25B in 2025, up $181M YoY; investing outflows increased $921M; financing activities provided $136M vs $-941M prior year
- Capital allocation: $94M in common stock repurchases in 2025; dividends increased to $1.22/share annually; $168M development commitments, $9.8B total debt with recent issuances and repayments
- Forward outlook: Management expects sufficient liquidity for operations, debt service, distributions, and capital needs; notes risks from credit rating downgrades and market conditions impacting borrowing costs
Risk Factors
- U.S. federal policy shifts (NIH funding cuts, drug pricing, tariffs) creating life science tenant funding uncertainty, risking rent payment and expansion
- Exposure to Medicare/Medicaid funding cuts and Affordable Care Act subsidy expiration impacting tenants in non-expansion states, affecting outpatient medical segment revenues
- Tariffs and supply chain disruptions raising construction costs and delaying development projects, increasing capital access risk
- Competition risk from international biotech sectors in China with favorable regulations diverting R&D investment away from U.S. lab tenants
- Tenant insolvency risk under U.S. Bankruptcy Code limiting lease remedies and delaying rent collections, especially under master leases across multiple properties
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.